论文部分内容阅读
重组α_(2a)干扰素（rIFN-α_(2a)和rIFN-α_(2b)可以诱导大多数慢性粒细胞性白血病（CML）患者血液学缓解,为了比较这两种rIFN制品的免疫原性,作者进行了一项随机调查,并研究了rIFN-α_2抗体的产生与治疗产生继发性耐药性的关系。 作者在相同条件下对新近诊断为CML的164例病人使用rIFN-α_2进行治疗,同时检测他们血清有无抗IFN-α_2抗体出现。参加试验的病人任选一种干扰素,剂量为500万U/m~2。整个研究中,两组病人在年龄、性别、
Recombinant alpha 2a interferon (rIFN-alpha 2a and rIFN alpha 2b) can induce hematologic relief in most patients with chronic myelogenous leukemia (CML). To compare the immunogenicity of these two rIFN products, The authors conducted a randomized trial and investigated the relationship between the production of rIFN-α 2 antibodies and the development of secondary drug resistance.164 cases of newly diagnosed CML under the same conditions were treated with rIFN-α 2, At the same time test their serum with or without anti-IFN-α 2 antibody.Patients to participate in the trial of a choice of interferon, a dose of 5 million U / m ~ 2. Throughout the study, two groups of patients in age, gender,